Orsini to Serve as Specialty Pharmacy Partner for Priovant's LISRAYA™ (brepocitinib)

PartnershipLISRAYAPositive

AI Analysis

Summary

Orsini announced it will serve as a specialty pharmacy partner for Priovant's LISRAYA (brepocitinib), the first FDA-approved targeted therapy for dermatomyositis. This is a routine distribution and partnership announcement.

Importance:4/10

Sentiment:

0.30

specialty pharmacyFDA approvedrare diseasedermatomyositispartnership

Related Companies

$TRAX

Read the original article

Published by PR Newswire Pharma on August 28, 2026 3:41 PM

Read Original